Recently, some studies have suggested that high expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells (CSCs/CICs) in the novel epithelioid sarcoma cell line ESX and might be a CSCs/CIC marker in epithelioid sarcoma. The studies indicated that CD109 may be a promising prognostic biomarker and a molecular target of cancer therapy for sarcomas. In another study, Cuppini et al. reported that CD109 is highly expressed in circulating endothelial and progenitor cells in recurrent glioblastomas. CD109, a glycosylphosphatidylinositol-anchored protein, is a member of the α2 macroglobulin/C3, C4, C5 family of thioester-containing proteins, and high expression of the CD109 gene was detected in approximately half of examined lung, esophageal, and cervical squamous cell carcinomas.
Tao J, et al. CD109 is a potential target for triple-negative breast cancer[J]. Tumor Biology, 2014, 35(12): 12083-12090.